Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank89
3Y CAGR+16.0%
5Y CAGR+13.8%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+16.0%/yr
vs +14.7%/yr prior
5Y CAGR
+13.8%/yr
Consistent
Acceleration
+1.3pp
Accelerating
Percentile
P89
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $292.98M | -28.2% |
| 2024 | $407.94M | +70.7% |
| 2023 | $238.93M | +27.4% |
| 2022 | $187.51M | +0.8% |
| 2021 | $186.08M | +21.2% |
| 2020 | $153.56M | -7.9% |
| 2019 | $166.68M | +54.1% |
| 2018 | $108.16M | +65.4% |
| 2017 | $65.40M | +172.5% |
| 2016 | $24.00M | - |